Is Omnicell Inc (OMCL) overvalued? · P/E 90, rev $1.11B
Omnicell Inc (OMCL) is a health information services company listed on NASDAQ.
This page asks whether Omnicell Inc (OMCL) looks expensive on cached numbers — not a short thesis.
Latest reported OMCL revenue for 2024-12-31 was $1.11B. Net income was $12.5M. Revenue was down 3.0% from 2023-12-31 to 2024-12-31. OMCL currently screens at market cap $1.80B and trailing P/E 89.9.
OMCL currently screens at market cap $1.80B and trailing P/E 89.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next OMCL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the OMCL stock page for the full model, not this heading.
Not investment advice.